Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Non-cash Items (2019 - 2022)

C4 Therapeutics (CCCC) has 4 years of Non-cash Items data on record, last reported at $1.7 million in Q1 2022.

  • For Q1 2022, Non-cash Items rose 214.0% year-over-year to $1.7 million; the TTM value through Mar 2022 reached $1.7 million, up 214.0%, while the annual FY2021 figure was $75.5 million, 26.4% down from the prior year.
  • Non-cash Items reached $1.7 million in Q1 2022 per CCCC's latest filing, down from $75.5 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $102.6 million in Q4 2020 and bottomed at $531248.0 in Q1 2021.
  • Average Non-cash Items over 4 years is $24.8 million, with a median of $3.2 million recorded in 2019.
  • Peak YoY movement for Non-cash Items: surged 2037.78% in 2020, then tumbled 90.14% in 2021.
  • A 4-year view of Non-cash Items shows it stood at $4.8 million in 2019, then soared by 2037.78% to $102.6 million in 2020, then dropped by 26.4% to $75.5 million in 2021, then plummeted by 97.79% to $1.7 million in 2022.
  • Per Business Quant database, its latest 3 readings for Non-cash Items were $1.7 million in Q1 2022, $75.5 million in Q4 2021, and $1.1 million in Q3 2021.